PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GeneType”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that the Know Your Risk event held yesterday at The Langham Pasadena has set a new standard for women’s health initiatives, highlighting the transformative potential of genetic testing and risk assessment. Organized by GeneType and Humanise Health, in partnership with Thermo Fisher Scientific and Creators Entertainment Group, this landmark event was not merely a gathering, but a movement aimed at empowering women with the knowledge to take control of their health.
A Movement, Not Just an Event
The Know Your Risk event was designed to foster an environment where women could engage with cutting-edge discussions on genomics and the importance of personalized health strategies. Through thought-provoking sessions led by renowned healthcare professionals, attendees explored how genetic testing and risk assessment can revolutionize preventive healthcare for women.
Inspirational Speakers and Insightful Panels
Co-hosted by the esteemed Dr. Kristi Funk and the dynamic Krystal Barter, the event featured a series of enlightening panels. Dr. Funk, Angelina Jolie’s Breast Surgeon, and Krystal Barter, along with an impressive lineup of speakers including Dr. Carolynn Young, Andrea Hans, Allyn Rose Oertel, and Matthew Zachary, provided invaluable insights into the critical role of genomics in women’s health.
Key Sessions Included:
Unpacking the Gender Health Gap: The Vital Role of Genetic Testing and Risk Assessment in Cancer Prevention for Women’s Health – Dr. Kristi Funk, Dr. Carolynn Young, and Krystal Barter delved into how genetic testing can identify risks early, bridging the gap in gender-specific healthcare.
Patient Voices at the Center: Lived Experiences in Women’s Health Advocacy and Policy – Andrea Hans, Matthew Zachary, and Allyn Rose Oertel shared personal stories and discussed the impact of patient advocacy on health policies and practices.
Launch of the Revolutionary GeneType Test
A highlight of the event was the launch of the groundbreaking geneType hereditary breast and ovarian cancer test. This innovative test is designed to identify 100 percent of women at risk, including those with the most common gene mutations, regardless of family history. This advancement represents a significant leap forward in preventive healthcare, offering women the tools they need to make informed decisions about their health.
A Transformative Experience
The Know Your Risk event successfully created a platform for education, empowerment, and community. It underscored the importance of genetic testing and risk assessment in transforming women’s health, inspiring attendees to advocate for their health and well-being proactively.
Enquiries
Simon Morriss
Chief Executive Officer
E: investors@genetype.com
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
About GeneType and Humanise Health
GeneType and Humanise Health are at the forefront of personalized healthcare, committed to advancing women's health through innovative genetic testing and comprehensive risk assessment.
Forward Looking Statements
This announcement may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
